journal article·2024-08Open access

The Loss of an Orphan Nuclear Receptor NR2E3 Augments Wnt/β‐catenin Signaling via Epigenetic Dysregulation that Enhances Sp1‐β catenin‐p300 Interactions in Hepatocellular Carcinoma

Yuet‐Kin Leung, Sung‐Gwon Lee, Jiang Wang, Ponmari Guruvaiah, Nancy J Rusch, Shuk‐Mei Ho, Chungoo Park, Kyounghyun Kim

Advanced Science· Volume 11· Issue 29

Abstract

Abstract The orphan nuclear receptor NR2E3 (Nuclear receptor subfamily 2 group E, Member 3) is an epigenetic player that modulates chromatin accessibility to activate p53 during liver injury. Nonetheless, a precise tumor suppressive and epigenetic role of NR2E3 in hepatocellular carcinoma (HCC) development remains unclear. HCC patients expressing low NR2E3 exhibit unfavorable clinical outcomes, aligning with heightened activation of the Wnt/β‐catenin signaling pathway. The murine HCC models utilizing NR2E3 knockout mice consistently exhibits accelerated liver tumor formation accompanied by enhanced activation of Wnt/β‐catenin signaling pathway and inactivation of p53 signaling. At cellular level, the loss of NR2E3 increases the acquisition of aggressive cancer cell phenotype and tumorigenicity and upregulates key genes in the WNT/β‐catenin pathway with increased chromatin accessibility. This event is mediated through increased formation of active transcription complex involving Sp1, β‐catenin, and p300, a histone acetyltransferase, on the promoters of target genes. These findings demonstrate that the loss of NR2E3 activates Wnt/β‐catenin signaling at cellular and organism levels and this dysregulation is associated with aggressive HCC development and poor clinical outcomes. In summary, NR2E3 is a novel tumor suppressor with a significant prognostic value, maintaining epigenetic homeostasis to suppress the Wnt/β‐catenin signaling pathway that promotes HCC development.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Epigenetics and DNA Methylation · Cancer-related gene regulation · Wnt/β-catenin signaling in development and cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmacology and Toxicology College of Medicine University of Arkansas Medical Sciences Little Rock AR 72205 USA

School of Biological Sciences and Technology Chonnam National University Gwangju 500‐757 Republic of Korea

Department of Pathology and Laboratory Medicine College of Medicine University of Cincinnati 231 Albert Sabin Way Cincinnati OH 45267 USA

Funding

Office of the Vice Chancellor for Research and Innovation · National Institute of Environmental Health Sciences · National Institute of General Medical Sciences · Arkansas Biosciences Institute

References (45)

Show source-provided references
1. 10.1053/j.gastro.2020.02.06810.1053/j.gastro.2020.02.068 ↗
2. 10.1038/s43018-022-00357-210.1038/s43018-022-00357-2 ↗
3. 10.1016/j.jhepr.2020.10016710.1016/j.jhepr.2020.100167 ↗
4. 10.3390/genes1407132510.3390/genes14071325 ↗
5. 10.1002/emmm.20110018710.1002/emmm.201100187 ↗
6. 10.1016/j.toxlet.2015.06.170810.1016/j.toxlet.2015.06.1708 ↗
7. 10.1038/s41598-017-11106-210.1038/s41598-017-11106-2 ↗
8. 10.1096/fj.201801881RR10.1096/fj.201801881RR ↗
9. 10.3390/cancers1107092610.3390/cancers11070926 ↗
10. 10.2147/JHC.S15670110.2147/JHC.S156701 ↗
11. 10.1046/j.1440-1746.2002.02774.x10.1046/j.1440-1746.2002.02774.x ↗
12. Inagawa S. · Clin. Cancer Res. · 2002 · 8 · 450
13. 10.20517/2394-5079.2017.0710.20517/2394-5079.2017.07 ↗
14. 10.1016/j.ebiom.2018.12.05810.1016/j.ebiom.2018.12.058 ↗
15. 10.1002/1878-0261.1215310.1002/1878-0261.12153 ↗
16. 10.1007/s11357-023-00742-410.1007/s11357-023-00742-4 ↗
17. 10.1073/pnas.050658010210.1073/pnas.0506580102 ↗
18. 10.1038/ng.367310.1038/ng.3673 ↗
19. 10.1016/j.jhep.2012.08.00810.1016/j.jhep.2012.08.008 ↗
20. 10.7554/eLife.1597810.7554/eLife.15978 ↗
21. 10.1053/j.gastro.2005.04.01310.1053/j.gastro.2005.04.013 ↗
22. 10.1158/0008-5472.CAN-07-090810.1158/0008-5472.CAN-07-0908 ↗
23. 10.1016/j.molcel.2010.05.00410.1016/j.molcel.2010.05.004 ↗
24. 10.1038/s41467-019-09780-z10.1038/s41467-019-09780-z ↗
25. 10.1038/nprot.2011.44410.1038/nprot.2011.444 ↗
26. 10.1016/j.molcel.2010.05.00410.1016/j.molcel.2010.05.004 ↗
27. 10.1093/nar/gkz106210.1093/nar/gkz1062 ↗
28. 10.1016/j.canlet.2017.06.01410.1016/j.canlet.2017.06.014 ↗
29. 10.3390/ijms2204185410.3390/ijms22041854 ↗
30. 10.1128/MCB.00188-1810.1128/MCB.00188-18 ↗
31. 10.1093/emboj/19.8.183910.1093/emboj/19.8.1839 ↗
32. 10.1046/j.1365-2443.2000.00302.x10.1046/j.1365-2443.2000.00302.x ↗
33. 10.7150/thno.7322310.7150/thno.73223 ↗
34. 10.1158/0008-5472.CAN-20-132310.1158/0008-5472.CAN-20-1323 ↗
35. 10.3892/ijo.2015.328810.3892/ijo.2015.3288 ↗
36. 10.1186/1479-5876-9-510.1186/1479-5876-9-5 ↗
37. 10.3892/ol.2016.463410.3892/ol.2016.4634 ↗
38. 10.3748/wjg.v11.i16.239810.3748/wjg.v11.i16.2398 ↗
39. 10.1158/0008-5472.CAN-09-309010.1158/0008-5472.CAN-09-3090 ↗
40. 10.3390/cancers1310235510.3390/cancers13102355 ↗
41. 10.1016/j.cell.2005.04.01410.1016/j.cell.2005.04.014 ↗
42. 10.1126/science.114048510.1126/science.1140485 ↗
43. 10.1111/j.1600-0676.1997.tb00803.x10.1111/j.1600-0676.1997.tb00803.x ↗
44. 10.1158/0008-5472.CAN-07-601310.1158/0008-5472.CAN-07-6013 ↗
45. 10.1093/nar/gkx24710.1093/nar/gkx247 ↗